康諾亞生物(02162.HK)料於年內就新藥CM310向國家藥監局提交新藥申請

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

康諾亞生物(02162.HK)料於年內就新藥CM310向國家藥監局提交新藥申請

阿思達克 10-11 16:33

康諾亞生物(02162.HK)公佈，旗下1類新藥CM310(通用名：Stapokibart)重組人源化單克隆抗體注射液，用於治療中重度特應性皮炎(AD)的三期註冊性臨牀試驗頂線數據，已於2023年歐洲皮膚病與性病學會(EADV)年會上發佈，療效結果顯示該試驗在第16周達到共同主要終點。集團表示，目前正就CM310治療成年人中重度特應性皮炎的新藥申請(NDA)與國家藥監局進行溝通，預期將於2023年提交新藥申請。

康诺亚-B(02162.HK)

Relevant Stocks

康诺亚-B(02162.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

康諾亞生物(02162.HK)料於年內就新藥CM310向國家藥監局提交新藥申請

Services

About Us

Agreement Statement